These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 9258601)

  • 21. Antisense strategies for the control of aberrant gene expression.
    Sczakiel G
    J Hematother; 1994; 3(4):305-13. PubMed ID: 7735826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antisense strategies for the treatment of hematological malignancies and solid tumors.
    Kronenwett R; Haas R
    Ann Hematol; 1998; 77(1-2):1-12. PubMed ID: 9760146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antisense therapy for cancer--the time of truth.
    Jansen B; Zangemeister-Wittke U
    Lancet Oncol; 2002 Nov; 3(11):672-83. PubMed ID: 12424069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antisense applications for biological control.
    Pan WH; Clawson GA
    J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The potential application of ribozymes for the treatment of hematological disorders.
    James HA
    J Leukoc Biol; 1999 Sep; 66(3):361-8. PubMed ID: 10496304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides.
    Hélène C
    Eur J Cancer; 1991; 27(11):1466-71. PubMed ID: 1835863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oligonucleotide-mediated modulation of mammalian gene expression.
    Scanlon KJ; Ohta Y; Ishida H; Kijima H; Ohkawa T; Kaminski A; Tsai J; Horng G; Kashani-Sabet M
    FASEB J; 1995 Oct; 9(13):1288-96. PubMed ID: 7557018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antisense molecules for targeted cancer therapy.
    Wacheck V; Zangemeister-Wittke U
    Crit Rev Oncol Hematol; 2006 Jul; 59(1):65-73. PubMed ID: 16750913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MDM2 and its splice variant messenger RNAs: expression in tumors and down-regulation using antisense oligonucleotides.
    Bartel F; Harris LC; Würl P; Taubert H
    Mol Cancer Res; 2004 Jan; 2(1):29-35. PubMed ID: 14757843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antisense oligonucleotides are clinically tested. They inhibit the expression of disease-related genes].
    Sommer W; Heilig M
    Lakartidningen; 1999 Jan; 96(4):348-54. PubMed ID: 10024826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antisense anticancer oligonucleotide therapeutics.
    Wang H; Prasad G; Buolamwini JK; Zhang R
    Curr Cancer Drug Targets; 2001 Nov; 1(3):177-96. PubMed ID: 12188878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antisense protein kinase A RI alpha-induced tumor reversion: portrait of a microarray.
    Cho-Chung YS
    Biochim Biophys Acta; 2004 Mar; 1697(1-2):71-9. PubMed ID: 15023351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oligonucleotides as modulators of cancer gene expression.
    Curcio LD; Bouffard DY; Scanlon KJ
    Pharmacol Ther; 1997; 74(3):317-32. PubMed ID: 9352587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The therapeutic potential of microRNAs in cancer.
    Thorsen SB; Obad S; Jensen NF; Stenvang J; Kauppinen S
    Cancer J; 2012; 18(3):275-84. PubMed ID: 22647365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells.
    Ho SM; Lau KM; Mok SC; Syed V
    Oncogene; 2003 Jul; 22(27):4243-56. PubMed ID: 12833147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antisense technologies have a future fighting neurodegenerative diseases.
    Seidman S; Eckstein F; Grifman M; Soreq H
    Antisense Nucleic Acid Drug Dev; 1999 Aug; 9(4):333-40. PubMed ID: 10463077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of colon cancer cell proliferation by antisense oligonucleotides targeting the messenger RNA of the Ki-ras gene.
    Sakakura C; Hagiwara A; Tsujimoto H; Ozaki K; Sakakibara T; Oyama T; Ogaki M; Imanishi T; Yamazaki J; Takahashi T
    Anticancer Drugs; 1995 Aug; 6(4):553-61. PubMed ID: 7579559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The application of antisense technology in ophthalmology].
    Guo Y; Ge J
    Yan Ke Xue Bao; 1998 Jun; 14(2):108-15. PubMed ID: 12580046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. c-myc antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer.
    Robinson LA; Smith LJ; Fontaine MP; Kay HD; Mountjoy CP; Pirruccello SJ
    Ann Thorac Surg; 1995 Dec; 60(6):1583-91. PubMed ID: 8787447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.